Johnson & Johnson JNJ

$263.81 -3.80 (-1.42%)

Valuation

Market cap
635,072,512,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
25.13
Forward PE
24.07
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,309,100
Avg volume
6,964,168
Day's range
$262.40 – $266.03
Shares out
2,407,310,000
Stochastic %K
76%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Quantumup Oct 26, 10:28 AM
Stifel⬆️ $ORIC's PT to $18 from $14 and reiterated Buy after de-risking presentations for ORIC at ESMO $PFE $JNJ AZN DSNKY IPSEY BAYRY AVBP CGEM Here's what Stifel said in its note: https://x.com/Quantumup1/status/2114664999587029458?s=20
0 replies
Stocktradesmoon Oct 26, 10:21 AM
$ABCL 👀 $MRNA $PFE $SLS $JNJ 🚨🚨🚨BREAKING NEWS: HOPEFULLY YOU ALL BOUGHT THE DIP LAST WEEK!!! HUGE BREAKOUT COMING NEXT WEEK STARTING MONDAY!!!! MARK THIS POST. HUGE DATA RELEASED LAST NIGHT SATURDAY OCT. 24th!!!!! (HONESTLY I CAN’T BELIEVE THAT INVESTORS AREN’T TALKING ABOUT IT YET!!!!) EXCUSE MY LANGUAGE BUT THIS IS A BIG F***** DEAL!!! $ABCL 🚨 — HUGE NEW PHASE 3 DATA FOR T-CELL ENGAGERS! 🧬🔥 Amgen just released detailed results from its Phase 3 DeLLphi-305 trial at ESMO 2026, and the numbers are incredible. 💥 58% reduction in the risk of death 💥 Median overall survival: 21.1 months vs. 12.7 months 💥 One-year survival: 79% vs. 53% 💥 Progression-free survival: 7.4 months vs. 1.9 months This is a T-cell engager treating one of the most aggressive forms of lung cancer! The trial’s success was announced in September, but these detailed survival numbers were released Saturday, October 24.
1 replies
abubnic Oct 25, 11:07 PM
$JNJ #ESMO Johnson & Johnson advances the next generation of solid tumor therapies with new data at ESMO 2026. First readout following acquisition of the RIPTAC™ platform shows promising anti-tumor activity with JNJ-6143, a novel oral investigational molecule, in difficult-to-treat prostate cancer. It offers a completely new way of thinking about cancer therapy.
0 replies
chursinow62 Oct 25, 10:39 PM
$JNJ $300 quick
0 replies
chursinow62 Oct 25, 10:39 PM
$JNJ Institutional houses loading in the AM JNJ breakthrough drug and expect another catalyst on Nov 19 with 95% buy in 🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 replies
Stocktradesmoon Oct 25, 10:35 PM
$ABCL 👀 $MRNA $PFE $SLS $JNJ 🚨🚨🚨BREAKING NEWS: HOPEFULLY YOU ALL BOUGHT THE DIP LAST WEEK!!! HUGE BREAKOUT COMING NEXT WEEK STARTING MONDAY!!!! MARK THIS POST. HUGE DATA RELEASED LAST NIGHT SATURDAY OCT. 24th!!!!! (HONESTLY I CAN’T BELIEVE THAT INVESTORS AREN’T TALKING ABOUT IT YET!!!!) EXCUSE MY LANGUAGE BUT THIS IS A BIG F***** DEAL!!! $ABCL 🚨 — HUGE NEW PHASE 3 DATA FOR T-CELL ENGAGERS! 🧬🔥 Amgen just released detailed results from its Phase 3 DeLLphi-305 trial at ESMO 2026, and the numbers are incredible. 💥 58% reduction in the risk of death 💥 Median overall survival: 21.1 months vs. 12.7 months 💥 One-year survival: 79% vs. 53% 💥 Progression-free survival: 7.4 months vs. 1.9 months This is a T-cell engager treating one of the most aggressive forms of lung cancer! The trial’s success was announced in September, but these detailed survival numbers were released TODAY, October 24.
2 replies
Stocktradesmoon Oct 25, 8:56 PM
$ABCL 👀 $MRNA $PFE $SLS $JNJ 🚨🚨🚨BREAKING NEWS: HOPEFULLY YOU ALL BOUGHT THE DIP LAST WEEK!!! HUGE BREAKOUT COMING NEXT WEEK STARTING MONDAY!!!! MARK THIS POST. HUGE DATA RELEASED LAST NIGHT SATURDAY OCT. 24th!!!!! (HONESTLY I CAN’T BELIEVE THAT INVESTORS AREN’T TALKING ABOUT IT YET!!!!) EXCUSE MY LANGUAGE BUT THIS IS A BIG F***** DEAL!!! $ABCL 🚨 — HUGE NEW PHASE 3 DATA FOR T-CELL ENGAGERS! 🧬🔥 Amgen just released detailed results from its Phase 3 DeLLphi-305 trial at ESMO 2026, and the numbers are incredible. 💥 58% reduction in the risk of death 💥 Median overall survival: 21.1 months vs. 12.7 months 💥 One-year survival: 79% vs. 53% 💥 Progression-free survival: 7.4 months vs. 1.9 months This is a T-cell engager treating one of the most aggressive forms of lung cancer! The trial’s success was announced in September, but these detailed survival numbers were released TODAY, October 24.
1 replies
TalkMarkets Oct 25, 8:19 PM
Is #JohnsonJohnson Stock A Buy After Its Prostate Cancer Pill Results? $JNJ https://talkmarkets.com/article/is-johnson-johnson-stock-a-buy-after-its-prostate-cancer-pill-results
0 replies